CN120225223A - 氯氮平诱导性流涎症改善剂 - Google Patents

氯氮平诱导性流涎症改善剂 Download PDF

Info

Publication number
CN120225223A
CN120225223A CN202380080815.2A CN202380080815A CN120225223A CN 120225223 A CN120225223 A CN 120225223A CN 202380080815 A CN202380080815 A CN 202380080815A CN 120225223 A CN120225223 A CN 120225223A
Authority
CN
China
Prior art keywords
clozapine
day
induced
dextromethorphan
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380080815.2A
Other languages
English (en)
Chinese (zh)
Inventor
新津富央
小田靖典
广濑祐纪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
Original Assignee
Chiba University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC filed Critical Chiba University NUC
Publication of CN120225223A publication Critical patent/CN120225223A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380080815.2A 2022-11-24 2023-11-22 氯氮平诱导性流涎症改善剂 Pending CN120225223A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022187772 2022-11-24
JP2022-187772 2022-11-24
PCT/JP2023/042038 WO2024111636A1 (ja) 2022-11-24 2023-11-22 クロザピン誘発性流涎症改善剤

Publications (1)

Publication Number Publication Date
CN120225223A true CN120225223A (zh) 2025-06-27

Family

ID=91195719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380080815.2A Pending CN120225223A (zh) 2022-11-24 2023-11-22 氯氮平诱导性流涎症改善剂

Country Status (4)

Country Link
EP (1) EP4623932A1 (https=)
JP (1) JPWO2024111636A1 (https=)
CN (1) CN120225223A (https=)
WO (1) WO2024111636A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264845A1 (en) * 2024-06-18 2025-12-26 Anavex Life Sciences Corp. Use of anavex3-71 for medical treatments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
PT3061821T (pt) 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
CN115245515A (zh) * 2021-04-27 2022-10-28 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2024111636A1 (ja) 2024-05-30
EP4623932A1 (en) 2025-10-01
JPWO2024111636A1 (https=) 2024-05-30

Similar Documents

Publication Publication Date Title
US11969431B2 (en) Formulations for treatment of post-traumatic stress disorder
AU2015217796B2 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
MX2015003812A (es) Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
JP2012500800A (ja) 神経因性疼痛の治療法
JP6336592B2 (ja) ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物
US20180177747A1 (en) Paediatric Compositions For Treating Multiple Sclerosis
CN120225223A (zh) 氯氮平诱导性流涎症改善剂
KR102266696B1 (ko) 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
US12582648B2 (en) Method for treating central nervous system disorders using dopamine D3 partial agonists
US8637263B1 (en) Assay for determination of compounds having anti-emetic activity
US10646457B2 (en) Emesis treatment
AU2009259950B2 (en) Paediatric compositions for treating1 multiple sclerosis
AU2019201291A1 (en) Paediatric compositions for treating multiple sclerosis
AU2018258970A1 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
HK1233960A1 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination